| Objective To study the effects of somatostatin combined with Xuebijing on acute cholecystitis(AC) and on liver function and serum inflammatory factors. Methods A total of 126 patients with AC treated in Hebei Seventh People’s Hospital from January 2022 to December 2022 were selected and divided into the experimental group (n=63) and the control group (n=63) according to random number table method. The control group received conventional symptomatic treatment combined with somatostatin treatment, and the experimental group received conventional symptomatic treatment together with somatostatin combined with Xuebijing treatment. The clinical signs of the two groups were observed, including the serum levels of hypersensitive C-reactive protein (Hs-CRP), procalcitonin (PCT), tumor necrosis factor-α (TNF-α) and other inflammatory factors before and after treatment; alanine aminotransferase (ALT), total bilirubin (TBIL), aspartate aminotransferase (AST), prealbumin (PA) and other liver function indicators. The adverse reactions and recurrence rate within three months were also compared. Results The disappearance time of nausea and vomiting, temperature return to normal, abdominal pain return time and diet return to normal time in experimental group were better than those in control group (P<0.05). After treatment, the serum levels of Hs-CRP, PCT, TNF-α, ALT, TBIL and AST in the experimental group were lower than those in the control group, and the levels of PA were higher than those in the control group, and the differences of each index before and after treatment were statistically significant (P<0.05). The clinical efficacy of the experimental group was better than that of the control group, and the recurrence rate of the experimental group was lower than that of the control group within three months after treatment, with statistical significance (P<0.05). Conclusion Somatostatin combined with Xuebijing in the treatment of AC can reduce the level of serum inflammatory factors, protect liver function and promote the recovery of patients, with significant efficacy, low recurrence rate, safety and reliability. |
